These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 36946781

  • 1. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA, Jefferson A, Chew-Martinez D, Matthews JS.
    Acc Chem Res; 2023 Jun 06; 56(11):1279-1286. PubMed ID: 36946781
    [Abstract] [Full Text] [Related]

  • 2. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.
    Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK.
    Expert Opin Ther Pat; 2022 Feb 06; 32(2):115-130. PubMed ID: 34657559
    [Abstract] [Full Text] [Related]

  • 3. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM, Abdulmalik O, El-Say KM, Ghatge MS, Cyril-Olutayo M, Paredes S, Al-Awadh M, El-Araby ME, Safo MK.
    Chem Biol Drug Des; 2024 Jan 06; 103(1):e14371. PubMed ID: 37798397
    [Abstract] [Full Text] [Related]

  • 4. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A, Ferrari M, Schleifer G, Cooper MK, Liu C, Yu B, Berra L, Klings ES, Safo RS, Chen Q, Musayev FN, Safo MK, Abdulmalik O, Bloch DB, Zapol WM.
    Mol Pharm; 2018 May 07; 15(5):1954-1963. PubMed ID: 29634905
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct 07; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
    Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, Dow RL, Fadeyi OO, Feng X, France SP, Howard RM, Janz JM, Jasti J, Jasuja R, Jones LH, King-Ahmad A, Knee KM, Kohrt JT, Limberakis C, Liras S, Martinez CA, McClure KF, Narayanan A, Narula J, Novak JJ, O'Connell TN, Parikh MD, Piotrowski DW, Plotnikova O, Robinson RP, Sahasrabudhe PV, Sharma R, Thuma BA, Vasa D, Wei L, Wenzel AZ, Withka JM, Xiao J, Yayla HG.
    J Med Chem; 2021 Jan 14; 64(1):326-342. PubMed ID: 33356244
    [Abstract] [Full Text] [Related]

  • 14. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP, Ghatge MS, Musayev FN, Deshpande TM, Chen Q, Braxton C, Kim S, Venitz J, Zhang Y, Abdulmalik O, Safo MK.
    Bioorg Med Chem; 2018 May 15; 26(9):2530-2538. PubMed ID: 29655608
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA.
    Blood; 2021 Sep 30; 138(13):1172-1181. PubMed ID: 34197597
    [Abstract] [Full Text] [Related]

  • 17. Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.
    Rab MAE, van Oirschot BA, Bos J, Kanne CK, Sheehan VA, van Beers EJ, van Wijk R.
    J Vis Exp; 2019 Nov 05; (153):. PubMed ID: 31762454
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM, Abdulmalik O, Ghatge MS, Muhammad YA, Paredes SD, El-Araby ME, Safo MK.
    Biomolecules; 2020 Nov 02; 10(11):. PubMed ID: 33147875
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK, Kato GJ.
    Hematol Oncol Clin North Am; 2014 Apr 02; 28(2):217-31. PubMed ID: 24589263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.